Jefferies Financial Group Inc. Acquires 410,188 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Jefferies Financial Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 44.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,339,814 shares of the biopharmaceutical company’s stock after purchasing an additional 410,188 shares during the period. Jefferies Financial Group Inc. owned 1.36% of Ultragenyx Pharmaceutical worth $20,137,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical by 295.4% in the third quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock worth $7,182,000 after acquiring an additional 357,005 shares during the last quarter. BlackRock Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $355,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $6,397,000. Deutsche Bank AG acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $5,503,000. Finally, Corient Private Wealth LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $4,644,000. 97.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on RARE shares. Wedbush reduced their price objective on Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating for the company in a research report on Wednesday, November 4th. Robert W. Baird lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $40.00 to $16.00 in a research report on Thursday, September 3rd. UBS Group initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Thursday, October 15th. They set a “neutral” rating and a $16.00 price target for the company. Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target for the company. in a report on Thursday, September 3rd. Finally, JPMorgan Chase & Co. lowered shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $80.00 to $36.00 in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Hold” and a consensus price target of $29.79.

Insider Activity

In other news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,510 shares of company stock valued at $127,561 over the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $16.70 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $12.73 and a 12-month high of $39.89. The business has a 50 day simple moving average of $15.47 and a 200 day simple moving average of $22.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million during the quarter, compared to analysts’ expectations of $182.49 million. During the same quarter in the prior year, the firm earned ($1.81) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 8.2% compared to the same quarter last year. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.21 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.